References
1. Yadav A, Carey EJ. Osteoporosis in chronic liver disease. Nutr Clin Pract. 2013;28(1):52–64.
2. Merli M, Berzigotti A, Zelber-Sagi S, et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol [Internet]. 2019;70(1):172–93. Available from: https://doi.org/10.1016/j.jhep.2018.06.024
3. Luxon BA. Bone disorders in chronic liver diseases. Curr Gastroenterol Rep. 2011;13(1):40–8.
4. Pietri M, Lucarini S. The orthopaedic treatment of fragility fractures. Clin Cases Miner Bone Metab. 2007;4(2):108–16.
5. George J, Ganesh HK, Acharya S, et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol. 2009;15(28):3516–22.
6. Wariaghli G, Allali F, Maghraoui A El, et al. Osteoporosis in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2010;22(12):1397–401.
7. Carey EJ, Balan V, Kremers WK, et al. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: Not just a cholestatic problem. Liver Transplant. 2003;9(11):1166–73.
8. Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol [Internet]. 2019;70(1):151–71. Available from: https://doi.org/10.1016/j.jhep.2018.09.014
9. Sheron N. Alcohol and liver disease in Europe - Simple measures have the potential to prevent tens of thousands of premature deaths. J Hepatol [Internet]. 2016;64(4):957–67. Available from: http://dx.doi.org/10.1016/j.jhep.2015.11.006
10. Yoon Y, Yi H. SURVEILLANCE REPORT 83 LIVER CIRRHOSIS MORTALITY IN THE UNITED STATES , 1970 – 2005 U . S . Department of Health and Human Services Public Health Service. 2008;
11. Santos LAA, Romeiro FG. Diagnosis and Management of Cirrhosis-Related Osteoporosis. Biomed Res Int. 2016;2016.
12. López-Larramona G, Lucendo AJ, González-Castillo S, et al. Hepatic osteodystrophy: An important matter for consideration in chronic liver disease. World J Hepatol. 2011;3(12):300–7.
13. Bansal RK, Kumar M, Sachdeva PRM, et al. Prospective study of profile of hepatic osteodystrophy in patients with non-choleastatic liver cirrhosis and impact of bisphosphonate supplementation. United Eur Gastroenterol J. 2016;4(1):77–83.
14. Choudhary NS, Tomar M, Chawla YK, et al. Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci. 2011;56(11):3323–7.
15. Cijevschi C, Mihai C, Zbranca E, et al. Osteoporosis in liver cirrhosis. Rom J Gastroenterol. 2005;14(4):337–41.
16. Peris P, Parés A, Guan̄abens N, et al. Bone mass improves in alcoholics after 2 years of abstinence. J Bone Miner Res. 1994;9(10):1607–12.
17. Branco JC, Rodrigues AM, Gouveia N, et al. Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: Results from EpiReumaPt- a national health survey. RMD Open. 2016;2(1).
18. Liang J, Meng WD, Yang JM, et al. The association between liver cirrhosis and fracture risk: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2018;89(4):408–13.
19. Nuti R, Brandi ML, Checchia G, et al. Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med [Internet]. 2019;14(1):85–102. Available from: https://doi.org/10.1007/s11739-018-1874-2
20. Xiang BY, Huang W, Zhou GQ, et al. Body mass index and the risk of low bone mass-related fractures in women compared with men: A PRISMA-compliant meta-analysis of prospective cohort studies. Med (United States). 2017;96(12):10–5.
21. Thursz M, Gual A, Lackner C, et al. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol [Internet]. 2018;69(1):154–81. Available from: https://doi.org/10.1016/j.jhep.2018.03.018
22. Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta-analysis. J Clin Endocrinol Metab. 2019;104(5):1623–30.
23. National Osteoporosis Guideline Group. NOGG 2017: Clinical Guidelines for the Prevention and Treatment of Osteoporosis. 2018;(July):1–36. Available from: https://www.sheffield.ac.uk/NOGG/NOGG Guideline 2017.pdf
1. Yadav A, Carey EJ. Osteoporosis in chronic liver disease. Nutr Clin Pract. 2013;28(1):52–64.
2. Merli M, Berzigotti A, Zelber-Sagi S, et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol [Internet]. 2019;70(1):172–93. Available from: https://doi.org/10.1016/j.jhep.2018.06.024
3. Luxon BA. Bone disorders in chronic liver diseases. Curr Gastroenterol Rep. 2011;13(1):40–8.
4. Pietri M, Lucarini S. The orthopaedic treatment of fragility fractures. Clin Cases Miner Bone Metab. 2007;4(2):108–16.
5. George J, Ganesh HK, Acharya S, et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol. 2009;15(28):3516–22.
6. Wariaghli G, Allali F, Maghraoui A El, et al. Osteoporosis in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2010;22(12):1397–401.
7. Carey EJ, Balan V, Kremers WK, et al. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: Not just a cholestatic problem. Liver Transplant. 2003;9(11):1166–73.
8. Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol [Internet]. 2019;70(1):151–71. Available from: https://doi.org/10.1016/j.jhep.2018.09.014
9. Sheron N. Alcohol and liver disease in Europe - Simple measures have the potential to prevent tens of thousands of premature deaths. J Hepatol [Internet]. 2016;64(4):957–67. Available from: http://dx.doi.org/10.1016/j.jhep.2015.11.006
10. Yoon Y, Yi H. SURVEILLANCE REPORT 83 LIVER CIRRHOSIS MORTALITY IN THE UNITED STATES , 1970 – 2005 U . S . Department of Health and Human Services Public Health Service. 2008;
11. Santos LAA, Romeiro FG. Diagnosis and Management of Cirrhosis-Related Osteoporosis. Biomed Res Int. 2016;2016.
12. López-Larramona G, Lucendo AJ, González-Castillo S, et al. Hepatic osteodystrophy: An important matter for consideration in chronic liver disease. World J Hepatol. 2011;3(12):300–7.
13. Bansal RK, Kumar M, Sachdeva PRM, et al. Prospective study of profile of hepatic osteodystrophy in patients with non-choleastatic liver cirrhosis and impact of bisphosphonate supplementation. United Eur Gastroenterol J. 2016;4(1):77–83.
14. Choudhary NS, Tomar M, Chawla YK, et al. Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci. 2011;56(11):3323–7.
15. Cijevschi C, Mihai C, Zbranca E, et al. Osteoporosis in liver cirrhosis. Rom J Gastroenterol. 2005;14(4):337–41.
16. Saeki C, Takano K, Oikawa T, et al. Comparative assessment of sarcopenia using the JSH , AWGS , and EWGSOP2 criteria and the relationship between sarcopenia , osteoporosis , and osteosarcopenia in patients with liver cirrhosis. 2019;4:1–12.
17. Peris P, Parés A, Guan̄abens N, et al. Bone mass improves in alcoholics after 2 years of abstinence. J Bone Miner Res. 1994;9(10):1607–12.
18. Branco JC, Rodrigues AM, Gouveia N, et al. Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: Results from EpiReumaPt- a national health survey. RMD Open. 2016;2(1).
19. Liang J, Meng WD, Yang JM, et al. The association between liver cirrhosis and fracture risk: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2018;89(4):408–13.
20. Nuti R, Brandi ML, Checchia G, et al. Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med [Internet]. 2019;14(1):85–102. Available from: https://doi.org/10.1007/s11739-018-1874-2
21. Xiang BY, Huang W, Zhou GQ, et al. Body mass index and the risk of low bone mass-related fractures in women compared with men: A PRISMA-compliant meta-analysis of prospective cohort studies. Med (United States). 2017;96(12):10–5.
22. Thursz M, Gual A, Lackner C, et al. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol [Internet]. 2018;69(1):154–81. Available from: https://doi.org/10.1016/j.jhep.2018.03.018
23. Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta-analysis. J Clin Endocrinol Metab. 2019;104(5):1623–30.
24. National Osteoporosis Guideline Group. NOGG 2017: Clinical Guidelines for the Prevention and Treatment of Osteoporosis. 2018;(July):1–36. Available from: https://www.sheffield.ac.uk/NOGG/NOGG Guideline 2017.pdf